Daily Stock Opinions and Ratings

Opinions

Peter Hodson Theratechnologies Inc TH-T BUY Oct 15, 2007

Had 2 good phase 3 trials. 2nd trial is going on right now. Long-term data was very effective. FDA approval will probably happen in the next year. Probably the best takeout candidate in a biotechnology space.

Peter Hodson

Owned

Unlock Rating

$12.150

Stock price when the opinion was issued

biotechnology pharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

BUY

Canadian. Excellent phase 3 product results. A take over target, in a position of being sold right now. They have lots of cash. At this level it’s a dollar below financing. Good product. Would buy at this price.

BUY

Excellent phase 3 results. They are a takeover target, they have lots of cash. Annoyed at management because last month they had 61 million in cash, and decided to put the company up for sale, while at the same time decided to raise money. They can't have it both ways. Nothing wrong with the product. Good one to hold and to buy. Should be stable.

TOP PICK

They are taking the profits and cash flow from their drug to introduce a second drug, expected next year. (Analysts’ target: $9.50).

PAST TOP PICK

(A Top Pick July 10/17 - Down 13%.) He knew it was high risk. The biggest risk would be a non-approval or delay on the process of getting a drug approved. A delay came to place. Still watch the story for the future.

RISKY

Had a sharp run, then a sharp pullback. Technically it looks good here. You could buy it here. But he doesn't know this company well.

PARTIAL BUY

Every biotech company always has some life-altering technology, and it's always way too positive. Small-mid caps like this can have big moves. Reversing a sideways trend, and breaking up to new levels, so that's positive. Maybe some movement up to $12. Take a small position, don't expose yourself too much. Support will be around $8.50, and if it breaks, start exiting.

BUY

If this was a fundamental disaster, it's going to be news driven. If it's the only company in the sector that's falling, tech analysis goes out the window. It's at a pocket after a big pullback. It's a gamble, but it's probably at a point to buy right now.

COMMENT

Biotechs can be very volatile. 2016 to early-2018 saw an uptrend, then turned down to the present. Be cautious now. TH-T is waiting for FDA approvals of its drugs which could swing this up sharply.

WAIT

Best quarter is the last one, which ends in February. December - May is optimal holding period. Lately, it's been trending lower. No reason to be enticed just yet. Want to see support at major moving averages.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

Peter Hodson Theratechnologies Inc TH-T BUY Oct 15, 2007

You might be interested:

Theratechnologies Inc(TH-T)

Theratechnologies Inc(TH-T)

Theratechnologies Inc(TH-T)

Theratechnologies Inc(TH-T)

Theratechnologies Inc(TH-T)

Theratechnologies Inc(TH-T)

Theratechnologies Inc(TH-T)

Theratechnologies Inc(TH-T)

Theratechnologies Inc(TH-T)

Latest Buy Signals

Today's Top Picks

Popular Articles

Latest Sell Signals

Most Recent Experts

Bruce Murray

The Panic-Proof Portfolio (Stockchase Research)

The Weekly Buzzing Stocks by Billy Kawasaki

Chris Blumas

Stockchase Insights